Purchase MDAI
Discount program, second order - 5%OFF, third order - 7% OFF
With us securely! - re-shipmentguarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not undercontrol before ordering.
We do not sell pharmaceutical products or controlledproducts.
Where to buy MDAI for sale
MDAI (5,6-methylenedioxy-2-aminoindane) is a novel, non-neurotoxic and highly selective serotonin-releasing agent (SSRA) in vitro with the potential for use as an antidepressant. MDAI was developed at the National Institute of Mental Health by a team from Purdue University under the supervision of David E. Nichols.
MDAI is a synthetic indoleamine that acts as a selective serotonin-releasing agent (SSRA) in vitro and produces psychedelic effects in humans. MDAI is known to produce entactogenic effects in human volunteers.
MDAI is a synthetic substance chemically related to other psychedelic drugs like LSD and psilocybin.
MDMA is a synthetic drug that acts as an empathogen, producing feelings of empathy and emotional closeness to others. It also produces entactogenic effects.
MDMA (3,4-methylenedioxymethamphetamine) is the salt form of a synthetic compound. X}
MDAI (5,6-methylenedioxy-2-aminoindane) is a highly potent and selective serotonin reuptake inhibitor (SSRI) that acts as a non-neurotoxic and highly selective serotonin-releasing agent (SSRA) in vitro. Results of animal studies indicate that MDAI may be effective in treating anxiety disorders as well as depression and obsessive-compulsive disorder.
MDAI (5,6-methylenedioxy-2-aminoindane) is a novel, selective serotonin reuptake inhibitor (SSRI) and selective serotonin releasing agent (SSRA), which acts as a non-neurotoxic and highly selective serotonin uptake inhibitor (SSRI) at low doses. Results of animal studies have indicated that MDAI may be a potentially effective pharmacological agent in the treatment of anxiety disorders as well as depression, obsessive-compulsive disorder, sleep disorders, and weight control. This compound has demonstrated superior efficacy to traditional SSRIs such as fluoxetine and sertraline in animal studies, indicating that it may possess fewer side effects than existing antidepressants.
MDAI (5,6-methylenedioxy-2-aminoindane) is a powerful, fast-acting drug with potent anti-depressant and anti-anxiety qualities. It might be useful in treating depression, OCD, PTSD and other psychiatric disorders.
A serotonin reuptake inhibitor (commonly known as an SSRI) is a drug that increases extracellular levels of the neurotransmitter serotonin by inhibiting its reuptake into the presynaptic cell. Contrary to popular belief, the "S" in SSRI does not stand for "serotonin" but for "selective."
The compound acts as a serotonin reuptake inhibitor, and it is highly potent.
MDAI 5,6-methylenedioxy-2-aminoindane is a high-affinity serotonin-releasing agent (HASRA) in vitro but produces opposite effects in vivo. MDAI is a selective serotonin reuptake inhibitor with moderate affinity for the serotonin transporter (SERT).
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin-releasing agent (SSRA) in vitro and produces entactogen effects in humans at low doses but does not have a dopamine release effect like most other hallucinogens.
MDAI is an entactogen that produces serotonin-mediated entactogenesis effects. MDAI has been used as a substitute for MDMA to avoid the neurotoxicity and dangers associated with MDMA abuse.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
-min-200x127.JPG)
